Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04727788 · ClinicalTrials.gov registry record
Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection
A clinical trial of Kidney Transplant Rejection, sponsored by Verici Dx.
- Active
- Registry status
- 550
- Enrollment target
- 13
- Study locations
NCT04727788: Active study of Kidney Transplant Rejection, sponsored by Verici Dx.
NCT04727788 is a study of Kidney Transplant Rejection that is active but no longer recruiting, run by Verici Dx. The registered enrollment target is 550 participants, below the 737-participant average among 8 other Kidney Transplant Rejection trials with a reported enrollment target (25% lower). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04727788, a study of Kidney Transplant Rejection, is active but no longer recruiting, sponsored by Verici Dx.
- ACTIVE NOT RECRUITING
- Registry status
- 550 participants
- Enrollment target
- 13
- Study locations
Study Summary
Global, non-randomized, observational study for the validation of Verici Dx genomic tests to predict risk of kidney clinical and subclinical acute rejection, and chronic allograft damage or interstitial fibrosis / tubular atrophy by correlating peripheral blood gene expression profiles with graft injury (e.g. cellular / antibody-mediated), rejection and death censored graft loss.
Primary Outcome
early acute rejection occurring within first 6 months, including borderline ACR
Conditions Studied
Study Locations (13)
Other
- CHU Grenoble Alpes Health Center - Grenoble
- Bologna University - Bologna
- Brescia University - Brescia
- University Hospital Vall d'Hebron, Barcelona - Barcelona
Illinois
- University of Illinois at Chicago - Chicago
- Northwestern University - Evanston
Maryland
- University of Maryland - Baltimore
Michigan
- Henry Ford - Detroit
Nebraska
- University of Nebraska Medical Center - Omaha
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- University of Pittsburgh - Pittsburgh
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2021-03-21 |
| Est. Completion | 2025-12-31 |
What the registry record for NCT04727788 still lists
NCT04727788 is an observational study that tracks outcomes without assigning an intervention. The registered 550 participants enrollment target is mid-sized for trials with a published cap, below the 737-participant average among 8 other Kidney Transplant Rejection trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Kidney Transplant Rejection appearing as the primary indexed condition, and to 0 interventions.
NCT04727788 lists 13 locations in 9 states (Other, Illinois, Maryland).
Frequently Asked Questions
What is clinical trial NCT04727788 about?
NCT04727788 is a clinical study titled "Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection". Global, non-randomized, observational study for the validation of Verici Dx genomic tests to predict risk of kidney clinical and subclinical acute rejection, and chronic allograft damage or interstitial fibrosis / tubular atrophy by correlating peripheral blood gene expression profiles with graft in...
What is the current status of trial NCT04727788?
This trial is currently active not recruiting. The enrollment target is 550 participants. The study started on 2021-03-21. Estimated completion is 2025-12-31.
What conditions does trial NCT04727788 study?
This clinical trial studies the following conditions: Kidney Transplant Rejection.
Who is sponsoring clinical trial NCT04727788?
This trial is sponsored by Verici Dx, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04727788 being conducted?
This trial has 13 study locations across Illinois, Maryland, Michigan, Nebraska, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04727788's enrollment target sits among peer trials
550 2nd of 8 the highest of 8 other Kidney Transplant Rejection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplant Rejection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trifecta-Kidney cfDNA-MMDx Study
RECRUITING
-
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
RECRUITING
-
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA
RECRUITING
-
Microbiome and Immunosuppression: The Mission Study
ACTIVE NOT RECRUITING
-
The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
ACTIVE NOT RECRUITING
-
Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
- NCT03474913 · 550 participants
Upright MRI for Prostate Cancer Screening
- NCT04761120 · 550 participants
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI